ClinicalTrials.gg
TerminatedNCT03968744Updated Mar 13, 2026

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

A Phase 4 interventional study of Safinamide in Idiopathic Parkinson's Disease (at Later Stage), sponsored by Alain Kaelin. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Alain Kaelin · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
insufficient eligible patients for enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing safinamide in Parkinson Disease — 1 open to participants now, 1 under way, 1 of them phase 3. safinamide · Parkinson Disease.

Enrollment
15th of 17
11 · median 103
Started
2019
with 3 others
Phase 4
4 of 17
none open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Alain Kaelin

Among the 17 studies testing safinamide in Parkinson Disease, this one is the 15th largest by enrollment, is one of 4 that started in 2019, is one of 4 in phase 4, and was the 14th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 17 studies testing safinamide in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About safinamide

safinamide: first FDA approval 2017 (XADAGO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing safinamide in Parkinson Disease, or all of them as a file.
02

Study summary

Patients suffering of Parkinson's Disease will be treated with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will be taken for 10 more weeks (maintenance phase). Total treatment 12 weeks.

Read the detailed description

Adult patients affected by PD and suffering from motor fluctuations will be screened for participation.

If the inclusion and exclusion criteria are met, the participant will enter in the baseline assessment phase and undergo 1 night baseline PSG and 1 week baseline actigraphy. The patient will then start the treatment with 50 mg/day of Safinamide per os for 2 weeks (escalation phase). Then, safinamide will be increased up to 100 mg/day and, if tolerated, the treatment will last for 10 weeks (maintenance phase). At week 12 (end of treatment), the questionnaires, actigraphy and PSG will be repeated. A safety follow-up visit is scheduled 4 weeks after study treatment completion.

The treatment will be continued thereafter in all patients if medically indicated.

03

Conditions studied

  • Idiopathic Parkinson's Disease (at Later Stage)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Fluctuating idiopathic PD patients according to UK Brain bank Criteria
  • Hoehn and Year II to IV under treatment
  • Sleep disturbance with a Pittsburgh Sleep Quality Index (PSQI) > 5
  • Treatment with L-DOPA, alone or with other dopaminergic drugs, at a stable dose since at least 28 days prior to inclusion
  • Treatment with all substances potentially acting on sleep and mood must be constant since at least 28 days prior to inclusion
  • Written
  • Willingness and ability to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Off label use of safinamide
  • Early PD or absence of PD fluctuations
  • Concomitant treatment with other MAO-B inhibitors (: at least 14 days)
  • Atypical Parkinsonism
  • Severe known sleep-related breathing disorders with any specific treatment or severe known sleep-related breathing disorders (apnoea-hypopnea index score >30/h) with or without a specific treatment
  • Dementia ( \< 26)
  • Severe depression (BDI-II ≥ 29)
  • Other severe psychiatric symptoms such as active psychosis or major hallucinations
  • Any previous or concomitant severe medical conditions or clinical laboratory abnormality which, in the clinical judgement of the Investigators, does not allow patients' participation into the study
  • Moderate or severe hepatic impairment, any type of retinopathy and/or any pathology that is deemed to be a according to safinamide's SmPC
  • Any concomitant treatment not allowed or contraindicated in the safinamide SmPC
  • Women who are pregnant or breast feeding
  • Lack of safe , defined as: Female participants of , not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Safinamide

    PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day

    Drug: Safinamide

Interventions

  • Safinamide taken per Os for 12 weeks

    Also known as: Xadago

06

What researchers measure

Primary outcomes

  1. Effect of safinamide on overall sleep quality

    To measure the change in PDSS-2 (Parkinson's Disease Sleep Scale Version 2) score and the changes in sleep maintenance (=total sleep time/partial sleep time) and sleep efficiency (=total sleep time/ time in bed) scores measured by polysomnography (PSG). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores \> 18 are considered as relevant sleep disturbances.

    Time frame: 12 weeks

Secondary outcomes

  1. Effect of safinamide on objective PSG sleep characterization

    To determine neurophysiological sleep parameters from PSG recording

    Time frame: 12 weeks

  2. Effect of safinamide on subjective sleep quality and sleepiness

    To measure the change in subjective sleep quality as measured by PDSS-2 subscores and by the electronic diary "Sleep Fit app", and in daytime sleepiness as measured by ESS (Epworth sleepiness scale) score. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores \> 18 are considered as relevant sleep disturbances. ESS score ranges from 0 to 24. Scores \> 10 suggest relevant daytime sleepiness.

    Time frame: 12 weeks

  3. Effect of safinamide on objective motor activity

    To determine the change in motor activity as measured by a specific objective measure of bradykinesia (FitTest) in the electronic diary "Sleep Fit app".

    Time frame: 12 weeks

  4. Effect of safinamide on subjective motor activity

    To measure the change in motor activity as measured by UPDRS (Unified Parkinson's Disease Rating Scale). Higher UPDRS score indicates more severe impairment of non-motor and motor activities.

    Time frame: 12 weeks

  5. Effect of safinamide on objective sleep parameters and motor symptoms

    To measure the change in sleep parameters and motor activity during the day and the night as measured by actigraphy.

    Time frame: 12 weeks

  6. Effect of safinamide on non-motor symptoms

    To measure the change in depressive symptoms as measured by (BDI-II) Beck Depression Inventory and SAS (Starkstein Apathy Scale). Total BDI-II score ranges from 0 to 63 with higher total score indicating more severe depressive symptoms. Total SAS score ranges from 0 to 42 with higher scores indicating more severe apathy.

    Time frame: 12 weeks

  7. Effect of safinamide on quality of life

    To measure the change in quality of life as measured by PDQ-39 (Parkinson's Disease Questionnaire-39). PDQ-39 is scored on a scale of 0 to 100, with lower scores indicating better health and high scores more severe symptoms.

    Time frame: 12 weeks

07

Study locations

1 site
  • Neurocenter of Southern Switzerland - Ente Ospedaliero Cantonale (EOC)
    Lugano, 6900, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Feb 2026, 83 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
May 30, 2019
StartActual
Feb 18, 2019
Primary completionActual
Feb 2, 2026
CompletionActual
Feb 2, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03968744
Lead sponsor
Alain Kaelin
Collaborators
Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Alain Kaelin (Director of Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
May 30, 2019
Start date
Feb 18, 2019
Primary completion
Feb 2, 2026
Completion
Feb 2, 2026
Last update
Mar 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safinamide

Start the discussion